Anorexia News and Research RSS Feed - Anorexia News and Research

AMPK protein activated during fasting regulates hunger neurons in the brain

AMPK protein activated during fasting regulates hunger neurons in the brain

Neurons in the brain that control hunger are regulated by AMPK, a protein activated during fasting, report researchers from Tufts University School of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School in Neuron on July 6, 2016. [More]
Body image-related problems growing among male individuals

Body image-related problems growing among male individuals

It’s referred to as the opposite of anorexia – muscle dysmorphia – but men with body-building and other body image issues are up to four times more likely than females to be undiagnosed and it is a growing public health problem. [More]
Novel anti-interleukin 1-alpha antibody shows promise in treating advanced colorectal cancer patients

Novel anti-interleukin 1-alpha antibody shows promise in treating advanced colorectal cancer patients

A novel anti-interleukin 1-alpha antibody has shown a significant impact on symptoms, and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data presented at the European Society for Medical Oncology's 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. [More]
Why does appetite loss occur during illness? An interview with Prof. Conti and Prof. Francesconi

Why does appetite loss occur during illness? An interview with Prof. Conti and Prof. Francesconi

Appetite, as a word, come from the Latin appetitus, meaning "desire for.” Therefore, appetite can be defined as a pleasurable sensation or the desire to eat. This sensation is coordinated by several brain areas associated with reward processing such amygdala, hippocampus, ventral pallidum, nucleus accumbens and striatum, and others. [More]
Study challenges notion of fear of weight gain in patients with anorexia nervosa

Study challenges notion of fear of weight gain in patients with anorexia nervosa

A study from Inserm, Paris Descartes University and Sainte Anne Hospital suggests that anorexia nervosa might not be explained by fear of gaining weight, but by the pleasure of losing it... and that the phenomenon might be genetically influenced. [More]
FDA approves blood-based cobas EGFR Mutation Test v2 for NSCLC patients

FDA approves blood-based cobas EGFR Mutation Test v2 for NSCLC patients

The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients. [More]
Investigational drug abemaciclib shows durable clinical activity for variety of cancer types

Investigational drug abemaciclib shows durable clinical activity for variety of cancer types

The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial. [More]
Women suffering from anorexia nervosa or obesity may respond differently to taste

Women suffering from anorexia nervosa or obesity may respond differently to taste

Researchers at the University of Colorado Anschutz Medical Campus have discovered that women suffering from anorexia nervosa and those who are obese respond differently to taste, a finding that could lead to new treatments for the eating disorders. [More]
Transcranial direct current stimulation proves effective for binge-eating disorder

Transcranial direct current stimulation proves effective for binge-eating disorder

Transcranial direct current stimulation, or tDCS, has proved effective for binge-eating disorder for the first time, according to researchers at the University of Alabama at Birmingham. [More]
Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. [More]
Combination of genetic, environmental risk factors can trigger fatal eating disorder in humans

Combination of genetic, environmental risk factors can trigger fatal eating disorder in humans

In a new study, researchers from Columbia University Medical Center described a new mouse model featuring a combination of genetic and environmental risk factors that can trigger the compulsive restriction of food intake seen in patients with anorexia nervosa. The findings may help to identify new prevention and treatment strategies for the eating disorder in humans. [More]
Radiation therapy plus PCV chemotherapy improves survival of low-grade glioma patients

Radiation therapy plus PCV chemotherapy improves survival of low-grade glioma patients

Patients with a low-grade type of brain tumor called glioma who received radiation therapy plus a chemotherapy regimen, including procarbazine, lomustine and vincristine (PCV), experienced a longer progression-free survival and overall survival than patients who received radiation therapy alone, according to the results of the clinical trial, Radiation Therapy Oncology Group 9802 published in the April 7 issue of the New England Journal of Medicine. [More]
Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. [More]
Helsinn, Mundipharma sign distribution, license and supply agreements for anamorelin

Helsinn, Mundipharma sign distribution, license and supply agreements for anamorelin

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announce that they have entered into distribution, license and supply agreements with Mundipharma and its network of independent associated companies granting exclusive rights to anamorelin in Norway, Finland, Sweden, Denmark and Iceland. [More]
Mortality risk higher in people with eating disorders

Mortality risk higher in people with eating disorders

Results from a newly published study indicate that individuals with eating disorders are at increased risk of death compared to the general population. Investigators found that individuals with anorexia nervosa (AN) had a five times higher mortality rate than their same age peers. [More]
Turing Pharmaceuticals emphasizes continued availability of Daraprim

Turing Pharmaceuticals emphasizes continued availability of Daraprim

Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases and conditions, today emphasizes the continued availability of Daraprim and cautions healthcare providers of proposed alternatives to Daraprim. [More]
Holidays can be a tough time for people with eating disorders

Holidays can be a tough time for people with eating disorders

With food everywhere you look, difficult relatives and pressure to create perfect memories, the holidays can be a tough time for those who struggle with eating disorders. [More]
Helsinn one step closer to bringing anamorelin HCI to market for treatment of anorexia, cachexia in NSCLC patients

Helsinn one step closer to bringing anamorelin HCI to market for treatment of anorexia, cachexia in NSCLC patients

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announced that the European Medicines Agency accepted for review, the marketing authorization application (MAA) for anamorelin HCI, a novel, orally active selective ghrelin receptor agonist under development for the treatment of anorexia, cachexia, or unintended weight loss in non-small cell lung cancer (NSCLC) patients. [More]
Bullies and victims at risk for eating disorders

Bullies and victims at risk for eating disorders

Being bullied in childhood has been associated with increased risk for anxiety, depression and even eating disorders. But according to new research, it's not only the victims who could be at risk psychologically, but also the bullies themselves. [More]
Research findings open up new avenues for treatment of people with anorexia nervosa

Research findings open up new avenues for treatment of people with anorexia nervosa

When people with anorexia nervosa decide what to eat, they engage a part of the brain associated with habitual behavior. This finding by researchers at Columbia University Medical Center, New York State Psychiatric Institute, the Mortimer B. Zuckerman Mind Brain Behavior Institute, and New York University was published today in Nature Neuroscience. [More]
Advertisement